The Rubin lab approach to cancer research has grown in parallel with the rapid expansion of bioinformatics and sequencing technology over the past 10 years.  Our expertise in identifying functional biomarkers and investigating prostate cancer heterogeneity has led to key discoveries in the distinction between indolent and aggressive cancer types.  Our mission is to identify potential therapeutic targets and bridge the latest in cancer genetics research with individual patient oriented clinical care. The Rubin lab is based in New York City at the Sandra and Edward Meyer Cancer Center of the Weill Cornell Medical College and New York-Presbyterian Hospital.


mark rubin lab cornell publications

Drawing from our expertise, read about our collaboration and lab research in recent publications.  [read more]

Lab News

mark rubin lab cornell

Read about our discoveries of treatment resistant bladder cancer, how we're developing precision medicine, and more news...[read more]

Our Research

rubin lab whole genome sequencing

The Rubin lab research team strives to identify new biomarkers in the pursuit of targeted cancer treatment. [read more]